Valuation: Mercury Laboratories Limited

Market Cap 840M 8.71M 7.64M 7.06M 6.49M 12.25M 12.44M 84.39M 33.08M 411M 32.71M 32M 1.42B P/E 2024
17.7x
P/E 2025 31.3x
Enterprise Value 879M 9.11M 7.99M 7.38M 6.79M 12.81M 13.02M 88.3M 34.61M 430M 34.23M 33.48M 1.48B EV / Sales 2024
1.29x
EV / Sales 2025 1.36x
Free-Float
13.68%
Yield 2024
0.42%
Yield 2025 0.43%
06-11 Mercury Laboratories Limited Announces Appointment of Binaya Kumar Panigrahi as Plant Head (Jarod Unit), Effective June 11, 2026 CI
05-29 Mercury Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
05-29 Mercury Laboratories Limited Recommends Dividend for the Financial Year Ended March 31, 2026 CI
05-29 Mercury Laboratories recommends final dividend of 3.50 rupees per share RE
04-29 Mercury Laboratories Limited Announces Resignation of Sandip Patel as Plant Head-Jarod, Effective April 28, 2026 CI
02-11 Mercury Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
11-11 Mercury Laboratories to establish SVP plant at 300 million rupees RE
11-11 Mercury Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
11-07 Mercury Laboratories Limited Announces Resignation of Mukesh Shrivastava as Vice President Marketing & Sales Designated as Senior Management Personnel, Effective from November 07, 2025 CI
11-04 Mercury Laboratories Limited Announces Appointment of Seema Salvi as Head of the Department (Dept.-Injectable Production), Effective November 04, 2025 CI
25-08-14 Mercury Laboratories Limited Approves Dividend for the Financial Year Ended March 31, 2025 CI
25-08-13 Mercury Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
25-08-13 Mercury Laboratories' Net Profit Rises in Fiscal Q1 MT
1 day+1.78%
1 week+6.16%
Current month+9.16%
1 month+0.95%
3 months+13.59%
6 months+7.35%
Current year+5.87%
1 week 767
Extreme 767
901.9
1 month 714.7
Extreme 714.7
901.9
Current year 620.55
Extreme 620.55
928.5
1 year 620.55
Extreme 620.55
976
3 years 620.55
Extreme 620.55
1,303
5 years 390
Extreme 390
1,303
10 years 212
Extreme 212
1,303
Manager TitleAgeSince
Chief Executive Officer 74 1982-02-15
Director of Finance/CFO 54 2021-10-20
Chief Operating Officer 41 2023-11-07
Director TitleAgeSince
Chairman 74 2015-02-22
Director/Board Member 71 1982-02-15
Director/Board Member 57 2017-09-30
Change 5-day change 1-year change 3-year change Capi.($)
+1.78%+6.16%-3.29%+6.29% 10.51M
-1.51%+1.10%+58.11%+15.62% 315B
-0.99%-3.50%+22.91%-10.98% 67.81B
-0.27%+1.80%+38.56%+82.01% 9.23B
+0.34%+0.51%+5.21%-1.87% 8.56B
-3.27%-6.80%-25.44%-5.88% 4.18B
+0.12%-11.96%-7.91%+16.33% 3.59B
-2.26%+1.02%-47.58%+21.10% 3.55B
-0.27%+1.12%+44.09%+56.22% 2.79B
+3.79%+1.33%+7.85%-21.52% 2.09B
Average -0.24%-1.24%+9.25%+15.73% 41.67B
Weighted average by Cap. -1.28%+1.91%+48.21%+12.32%

Financials

2024 2025
Net sales 756M 7.84M 6.87M 6.35M 5.84M 11.02M 11.19M 75.91M 29.76M 370M 29.42M 28.78M 1.27B 751M 7.79M 6.83M 6.31M 5.8M 10.95M 11.13M 75.45M 29.58M 367M 29.24M 28.61M 1.27B
Net income 56.54M 586K 514K 475K 437K 824K 838K 5.68M 2.23M 27.67M 2.2M 2.15M 95.32M 31.45M 326K 286K 264K 243K 459K 466K 3.16M 1.24M 15.39M 1.22M 1.2M 53.01M
Net Debt -25.4M -263K -231K -213K -196K -370K -376K -2.55M -1M -12.43M -989K -968K -42.82M 38.95M 404K 354K 327K 301K 568K 577K 3.91M 1.53M 19.06M 1.52M 1.48M 65.65M
Logo Mercury Laboratories Limited
Mercury Laboratories Limited is an India-based pharmaceutical company. The Company operates through the Pharmaceuticals Products segment. It is engaged in the manufacturing and export of a range of pharmaceutical items. The products of the Company are in the segment of gynecology and pediatrics. Its products include antibiotic, antifungal, and antiviral formulations; anti-inflammatory formulations; antimalarial formulations; digestive formulations; hypoglycemic formulations; multivitamin formulations; central nervous system formulations; gynec formulations; CVS formulations; cough and cold formulations; and miscellaneous formulations, and innovative products. Its antibiotic, antifungal, and antiviral formulations include azithromycin tablets, azithromycin dispersible tablets, griseofulvin tablets, metronidazole tablets, and others. Its anti-inflammatory formulations include dexamethasone tablets, glucosamine sulphate tablets, dexamethasone sodium phosphate injection, and others.
Employees
503
Date Price Change Volume
26-07-20 858.80 +1.78% 101
26-07-17 ₹843.75 -3.79% 163
26-07-16 ₹876.95 +10.18% 1,825
26-07-15 ₹795.90 -1.74% 22
26-07-14 ₹810.00 +1.22% 10
  1. Stock Market
  2. Stocks
  3. MERCURYLAB6 Stock